Amy L. Clark, DO

Washington University in St. Louis (WU)

The goal of my research is to delineate the molecular mechanisms of beta cell death resulting in type 1 diabetes (T1DM) to discover novel beta cell preserving therapies for diabetic patients. My research has shown that pharmacologic preservation of cellular calcium homeostasis can prevent cytokine mediated beta cell death in vitro. Further studies are underway to determine if these compounds are protective in animal models of diabetes. I am also actively studying the role of beta cell driven sterile inflammation in insulitis and beta cell death. Recent studies indicate that the ER stress related protein thioredoxin interacting protein (TXNIP) may be a key molecular mediator of hyperglycemia induced islet inflammation and beta cell death. Studies are underway utilizing in vivo and in vitro TXNIP knock out models to delineate the role and mechanism of TXNIP in the development and progression of T1DM.